|Bid||348.34 x 800|
|Ask||578.00 x 1100|
|Day's Range||390.00 - 399.90|
|52 Week Range||281.89 - 437.90|
|Beta (3Y Monthly)||1.72|
|PE Ratio (TTM)||28.70|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||408.33|
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.
PARIS and TARRYTOWN, N.Y., Oct. 16, 2018 /PRNewswire/ -- Two pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP") met all primary and secondary endpoints.
Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues. Sanofi and Regeneron ...
Dupixent ® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps Dupixent significantly reduced nasal polyp size, nasal congestion ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that both pivotal Phase 3 placebo-controlled trials evaluating Dupixent® (dupilumab) in adults with inadequately-controlled chronic rhinosinusitis with nasal polyps ("CRSwNP"), met all their primary and secondary endpoints.
Figuring out which healthcare stocks to buy has never been an easy task. President Trump has repeatedly blasted the Affordable Care Act, promising to overhaul our healthcare system. Naturally, many healthcare stocks have experienced a tumultuous ride in the markets under the Trump White House.
The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.
On the charts, Arrowhead Pharmaceuticals (NASDAQ: ARWR) showed a “double top,” touching around $20 twice between September and October, before crashing down more than 30% in the last week. As value investors will ask after such a drop…what happened? On Oct. 4, Arrowhead announced that it entered into a license and collaboration with Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ).
TARRYTOWN, N.Y. and PARIS, Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi will present a diverse set of data from their joint clinical program investigating Libtayo® (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1).
TARRYTOWN, N.Y. , Oct. 8, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2018 financial and operating results on Tuesday, November ...
With a market capitalization of US$43.5b, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is a large-cap stock, which is considered by most investors as a safe bet. Common characteristics for these big stocks Read More...
Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.
Sanofi (SNY) develops Dupixent in collaboration with Regeneron Pharmaceuticals (REGN). It’s currently approved for moderate-to-severe atopic dermatitis in adults. The drug is undergoing multiple late-stage trials for various other indications, which, if approved, could expand Sanofi’s market opportunities and growth potential for Dupixent.
Sanofi’s (SNY) Dupixent (dupilumab) is an interleukin-3 and interleukin-4 inhibitor that helps lower moderate-to-severe atopic dermatitis. It’s jointly developed by Sanofi and Regeneron (REGN). On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents aged 12 to 17 years.
Sanofi SA said on Friday its skin cancer drug, made in partnership with Regeneron Pharmaceuticals Inc, was approved by the U.S. Food and Drug Administration. The drug, Libtayo, is used to treat a rare form of skin cancer, in patients whose condition has not improved following surgery or chemotherapy. Metastatic cutaneous squamous cell carcinoma is the second-most common form of skin cancer, which accounts for an estimated 7,000 deaths in the United States each year, Sanofi said.
Regeneron Pharmaceuticals Inc. and Sanofi won U.S. Food and Drug Administration approval for their first immuno-oncology drug, a therapy that the companies hope will jump-start their cancer joint venture. Libtayo, also known as cemiplimab, treats a deadly form of skin cancer. It’s the first drug to come out of the companies’ 2015 partnership to research therapies that use the body’s immune system to fight various malignancies.
Sanofi and Regeneron Pharmaceuticals Inc. said late Friday the U.S. Food and Drug Administration has approved their drug Libtayo for the treatment of a common type of metastatic skin cancers that previously had no treatment. The medication was on priority review. Both companies will market the drug in the U.S. Shares of Regeneron rose 2% after the announcement, while the American depositary shares of Sanofi were flat in the extended session Friday.
* CSCC is the second most common skin cancer in the U.S. PARIS AND TARRYTOWN, N.Y., Sept. 28, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.
CSCC is the second most common skin cancer in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Libtayo® (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1) and is the first and only treatment specifically approved and available for advanced CSCC in the U.S.